RRML - SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English

SCImago Journal & Country Rank

Advanced search

Top 10 downloaded articles
- May 2020 -
Multiplex ligation-dependent p... 23
Romanian Review of Laboratory ... 14
The predictive role of platele... 14
Bone status and aortic calcifi... 12
Total antioxidant status as ma... 11
Cardiotoxicity - the first cau... 10
Implications of visfatin genet... 9
Genetic variability of ANG2 -3... 8
Levels of lactoferrin, lysozym... 7
Relationships between serum pr... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

Ahead of print DOI:10.2478/rrlm-2020-0025

Research article

SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms

Adrian P. Trifa, Diana L. Lighezan, Cristina Jucan, Florin Tripon, Dana R. Arbore, Anca Bojan, Ștefana Gligor-Popa, Raluca M. Pop, Delia Dima, Claudia Bănescu

Correspondence should be addressed to: Adrian P. Trifa


Background: Pathogenesis and phenotypic diversity in myeloproliferative neoplasms (MPN) cannot be fully explained by the currently known acquired mutations alone. Some susceptible germline variants of different genes have been proved to be associated with the development of these diseases. The goal of our study was to evaluate the association between the rs3184504 polymorphism of SH2B3 (LNK) gene (p.R262W, c.784T>C) and the risk of developing the four typical MPN - polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myeloid leukemia (CML). Material and methods: We investigated the SH2B3 rs3184504 T>C polymorphism by real-time PCR in 1901 MPN patients (575 with PV, 798 with ET, 251 with PMF, and 277 with CML), all of them harboring one of the specific driver mutations - JAK2 V617F or CALR in case of PV, ET and PMF, or BCR-ABL1 in case of CML, and 359 controls. Results: Overall, the TT homozygous genotype was significantly associated with BCR-ABL1-negative MPN (OR = 1.34; 95% CI = 1.03-1.74; crude p-value = 0.02; adjusted p-value = 0.04). The most significant association was seen in case of PV (OR = 1.54; 95% CI = 1.14-2.06; crude p-value = 0.004; adjusted p-value = 0.024). Also, SH2B3 rs3184504 correlated significantly with JAK2 V617F-positive MPN (OR = 1.36; 95% CI = 1.04 -1.77; crude p-value = 0.02; adjusted p-value = 0.08), but not with those CALR-positive. ET (regardless of molecular subtype) and CML were not correlated with SH2B3 rs3184504. Conclusions: The SH2B3 rs3184504 polymorphism is associated with risk of MPN development, especially PV. This effect is restricted to JAK2 V617F-positive PV and PMF only.

Keywords: myeloproliferative neoplasms, somatic mutations, genetic predisposition

Received: 15.2.2020
Accepted: 5.4.2020
Published: 12.4.2020

  PDF Download full text PDF
(409 KB)